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Ab1–42a2-Macroglobulin (a2M) is an extracellular chaperone that inhibits amorphous and fibrillar protein
aggregation. The reaction of a2M with proteases results in an ‘activated’ conformation, where the
proteases become covalently-linked within the interior of a cage-like structure formed by a2M. This
study investigates, the effect of activation on the ability of a2M to inhibit amyloid formation by
Ab1–42 and I59T human lysozyme and shows that protease-activated a2M can act via two distinct
mechanisms: (i) by trapping proteases that remain able to degrade polypeptide chains and (ii) by
a chaperone action that prevents misfolded clients from continuing along the amyloid forming
pathway.
Structured summary of protein interactions:
Ab1–42 and Ab1–42 bind by fluorescence technology (View interaction)
I59T lysozyme and I59T lysozyme bind by light scattering (View interaction)
I59T lysozyme and I59T lysozyme bind by fluorescence technology (View interaction)
Alpha-lactalbumin and Alpha-lactalbumin bind by fluorescence technology (View interaction)
I59T lysozyme and I59T lysozyme bind by electron microscopy (View interaction)
Ab1–42 and Ab1–42 bind by electron microscopy (View interaction)
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. Open access under 1. Introduction
a2-Macroglobulin is a highly abundant glycoprotein present in
blood plasma, cerebrospinal fluid and other extracellular fluids.
a2M is best known for its ability to trap a broad range of proteases
within a cage-like quaternary structure via covalent-linkage of the
protease to intramolecular thioester bonds on a2M [1]. This reac-
tion results in a conformationally altered form commonly known
as ‘‘activated’’ or ‘‘fast’’ a2M, the latter term relating to enhanced
mobility via native gel electrophoresis. Activation of a2M results
in the exposure of a cryptic receptor recognition site for the low-
density lipoprotein receptor-related protein (LRP) [1]. In addition
to proteases, small nucleophiles can activate a2M by interacting di-Along with protease trapping, many other biological functions
have been proposed for a2M; including roles in immunomodula-
tion, cancer progression and extracellular proteostasis [3–5]. a2M
can bind to a range of endogenous disease-associated proteins
including the amyloid b peptide (Ab1–42) [6], prion proteins [7]
and b2-microglobulin [8], which are the main components of
deposits found in Alzheimer’s disease (AD), spongiform encepha-
lopathies and dialysis-related amyloidosis, respectively [9]. More-
over, a2M is found to be co-localized in vivo with amyloid
deposits in AD and the spongiform encephalopathies [7,10]. Recent
work has shown that native a2M can act as an ATP-independent
molecular chaperone by suppressing stress-induced amorphous
protein aggregation [5]. The mechanism by which this occurs ap-
pears to involve the formation of stable, soluble complexes be-
tween a2M and the misfolded client proteins [5]. Native a2M has
also been shown to suppress the fibril formation of a range of amy-
loidogenic proteins and peptides [11,12]. It has been proposed that
a2M can protect against pathogenic misfolded proteins by promot-
ing their removal from the extracellular space [6,13,14]. However,
trypsin-activated a2M (trypsin-a2M) is reportedly unable to pre-ins [5].
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ability to become activated, and a2M-trypsin-misfolded protein
complexes are recognized by LRP [5], representing a potential
route for the targeted disposal of misfolded proteins in vivo.
Activated a2M can protect cells from Ab toxicity in vitro
through specific binding and subsequent LRP mediated uptake
and degradation of Ab140 [6,10,15]. While it is clear that activated
a2M can bind to Ab peptide, its ability to prevent the fibrillar
aggregation of amyloid forming peptides or proteins has not been
tested. To address this issue, we investigate the effect of activated
a2M on the fibril formation of the amyloidogenic Ab1–42 peptide
and of a non-natural variant of human lysozyme (I59T) that pos-
sesses many attributes associated with the natural amyloidogenic
variants linked to systemic amyloidosis [16].
2. Materials and methods
Chemicals and reagents were purchased from Sigma–Aldrich
Ltd. unless otherwise stated.
2.1. Proteins and peptides
a2M was purified from human plasma by zinc chelate affinity
chromatography and size exclusion chromatography (SEC) as pre-
viously described [5]. Purified a2M was stored at 4 C (for less than
2 months) and routinely examined prior to use by native polyacryl-
amide gel electrophoresis (PAGE) to ensure that the preparation
had not become partially degraded, activated or cross-linked, mod-
ifications that can occur with prolonged storage [4,17,18]. Ab1–42
was purchased from Biopeptide Co. Inc. or Bachem AG. Solutions
of Ab1–42 peptide were prepared by a TFA/HFIP dissolution method
[19]. The non-natural variant of human lysozyme, I59T, was ex-
pressed and purified as previously described [16].
2.2. Preparation of activated a2M
Trypsin-a2M was prepared by incubating a2M with a threefold
molar excess of bovine trypsin in PBS (pH 7.4, 25 C, 45 min). The
degree of a2M activation was assessed by NuPAGE Novex 3–8%
Tris–acetate gels with Tris–glycine native running buffer (Life
Technologies Ltd.). The reaction was allowed to continue for up
to an additional 45 min to ensure completion. Unreacted trypsin
was removed by SEC and SDS–PAGE analysis using NuPAGE Novex
4–12% Bis–Tris gels with MES running buffer (Life Technologies
Ltd.) confirmed that no cleavage outside the bait region had oc-
curred. To produce enzymatically inactivated trypsin-a2M (i.e.
(i)trypsin-a2M), trypsin-a2M was incubated (2 h, 25 C) with ex-
cess Complete™ protease inhibitor cocktail (Roche Diagnostics
Ltd.) and samples were desalted using Zeba™ desalting columns
(Thermo Fisher Scientific). Ammonium chloride (NH4Cl) activation
was performed by incubating a2M with 400 mM NH4Cl in PBS
(14 h, 25 C) and subsequently desalting as described.
2.3. Thioflavin-T assays
Ab1–42 (5 lM, PBS (pH 7.4), 50 lM ThT) was incubated in a 384
well plate (37 C, with shaking) using a FLUOstar OPTIMA fluores-
cence plate reader (BMG Labtech Ltd.) with excitation and emis-
sion wavelengths of 440 nm and 480 nm (slit-widths 10 nm).
I59T lysozyme (6.8 lM, 0.1 M citrate buffer (pH 5.0), 25 lM ThT)
was incubated with stirring at 60 C in a Cary Eclipse spectrofluo-
rimeter (Agilent Ltd.) and ThT fluorescence intensity was moni-
tored with excitation and emission wavelengths of 440 nm and
480 nm (slit-widths 5 nm). All samples incubated with native
a2M, trypsin-a2M, (i)trypsin-a2M, or NH4Cl-activated a2M con-
tained a molar ratio of substrate-to-a2M of 10:1, based on themolecular weights of the a2M tetramer (720 kDa), the Ab1–42
monomer (4.5 kDa) or the I59T monomer (14.7 kDa). All experi-
ments were performed in triplicate.
2.4. SDS–PAGE analysis
At the endpoints of the aggregation assays, aliquots were re-
moved and either centrifuged (10 min, 10000g) (I59T lysozyme
and Ab1–42) or filtered (0.22 lm filter) (I59T lysozyme). For I59T
lysozyme, the pellet fractions were rinsed with dH2O, centrifuged
again (10 min, 10000g) and then dissolved in 10 ll of 8 M urea
solution. The supernatants and solubilised pellets were separated
on 4–12% NuPAGE gels under reducing conditions. The gels were
stained with Coomassie Brilliant Blue or Sigma ProteoSilver stain
kit for I59T and Ab1–42, respectively. Additionally, Ab1–42 labelled
with Hilyte™ 488 (AnaSpec) was incubated with 10:1 substrate-
to-trypsin-a2M (30 min, 25 C) and centrifuged (10 min,
10000g). The supernatants were separated on 4–12% NuPAGE
gels and visualized using a Typhoon Trio Imager (GE Healthcare
Ltd).
2.5. Transmission electron microscopy (TEM)
Fibril solutions (5 ll) were applied to carbon-coated nickel
grids, stained with 2% (w/v) uranyl acetate, and imaged on a FEI
Tecnai G2 transmission electron microscope (Multi-Imaging Unit
in the Department of Physiology, Development and Neuroscience,
University of Cambridge, UK). Images were analyzed using the
SIS Megaview II Image Capture system (Olympus).3. Results
Native a2M has previously been shown to inhibit the amor-
phous and fibrillar aggregation of a range of proteins by increasing
their solubility [5,11,12,16]. To determine if activated a2M can also
prevent amyloid formation, we compared the effect of native a2M
and trypsin-a2M on the fibril formation of I59T lysozyme and the
amyloidogenic peptide Ab1–42. Previously reported conditions for
generating trypsin-a2M vary greatly [2,5,20]; therefore, in this
study we used an optimized method to obtain preparations of
trypsin-a2M that were completely activated but not degraded
(Supplementary Fig. 1). The aggregation behavior of I59T lysozyme
is well established and this system has been used to study the ef-
fects on fibril formation of the extracellular chaperones clusterin,
haptoglobin and native a2M [12,21]. In this study, the kinetics of
aggregation show a lag phase of ca. 50 min, followed by a rapid
growth phase that reaches a plateau after ca. 150 min (Fig. 1a,
black line). a2M, present at a molar ratio of 10:1 (lysozyme-to-
a2M), results in a dramatic decrease in thioflavin-T (ThT) fluores-
cence over the course of the assay (Fig. 1a; red line). When tryp-
sin-a2M is incubated with I59T lysozyme the ThT fluorescence is
again, significantly suppressed (Fig. 1a; blue line). At the endpoint
of the fibril formation, the presence of both native a2M and tryp-
sin-a2M results in over a 90% decrease in ThT signal relative to
the I59T lysozyme sample alone (Fig. 1b).
TEM images of the ThT assay endpoint samples demonstrate
that while I59T lysozyme alone forms fibrillar structures there is
no evidence for such structures when I59T lysozyme is incubated
under the same conditions with native a2M or trypsin-a2M
(Fig. 1c). SDS–PAGE analysis of the endpoint supernatants reveals
that no detectable I59T lysozyme remains in solution when incu-
bated alone, whereas in the presence of native a2M, a large major-
ity (>90%) of lysozyme remains soluble (Fig. 1d). The I59T lysozyme
also remains in the soluble fraction when incubated with trypsin-
a2M and shows no evidence of proteolytic degradation (Fig. 1d).
Fig. 1. Effects of a2M variants on I59T lysozyme fibril formation. (a) In vitro fibril formation of I59T lysozyme incubated alone (black), with native a2M (red), with trypsin-
a2M (blue) or with NH4Cl-activated a2M (green) using a2M-to-lysozyme molar ratios of 1:10. (b) Percent of maximum ThT signal at the endpoint of aggregation. Each bar
represents an average of three individual experiments. (c) TEM analysis of the endpoint samples in the absence or presence of the different a2M variants, with scale bars
representing 100 nm and numbers corresponding to the lanes in gel analysis. (d) SDS–PAGE of the endpoint supernatants shows no soluble protein in I59T lysozyme
incubated alone (1), whereas soluble protein is present for samples containing native a2M (2), trypsin-a2M (3) and NH4Cl-activated a2M (4). Soluble I59T lysozyme is shown
in lane S and lane M shows molecular mass markers. (e) SDS–PAGE of the solubilized endpoint pellets showing a significant quantity of protein present for I59T incubated
alone (1p), and also trace quantities of protein present for samples containing native a2M (2p), trypsin-a2M (3p) and NH4Cl-activated a2M (4p).
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a large proportion of I59T lysozyme in the I59T alone sample
(Fig. 1e, lane 1p) and only trace amounts (less than 10%) of lyso-
zyme present in samples incubated with native a2M and trypsin-
a2M (Fig. 1e, lane 2p and 3p). This finding is consistent with the
fraction of the maximum ThT signal observed at the aggregation
endpoints (Fig. 1b). In separate experiments, incubation of mono-
meric I59T lysozyme with trypsin or trypsin-a2M does not result
in the appearance of any degraded protein in the soluble fractions
after 120 min of incubation under the aggregation conditions used
(Supplementary Fig. 2a), in addition, trypsin alone has no effect on
I59T fibril formation (Supplementary Fig. 2b). However, it is noted
that small quantities of protein fragments (less than 5% total pro-
tein) are apparent in the SDS–PAGE analysis of the pellet samples
after 300 min incubation. These fragments may be the result ofresidual trypsin-a2M activity, but they appear to be aggregation
prone as they are only apparent in small quantities in the insoluble
pellet sample. Taken together these results reveal that, native a2M
and trypsin-a2M are able to suppress I59T fibril formation predom-
inantly via chaperone action.
We next evaluated whether trypsin-a2M could also suppress
Ab1–42 fibril formation. Under the conditions used here, aggrega-
tion of Ab1–42 shows a lag of ca. 70 min, followed by a rapid growth
phase and a plateau at ca. 150 min (Fig. 2a, black line). Consistent
with previous studies [12], the presence of native a2M at a 10:1
(Ab1–42-to-a2M) molar ratio dramatically reduces the time-depen-
dent increase in ThT fluorescence (Fig. 1a; red line). At the same
molar ratio, the presence of trypsin-a2M also results in a suppres-
sion of ThT fluorescence (Fig. 2a, solid blue line). This suppression
in ThT signal is over 80% for both the presence of native a2M and
Fig. 2. Effects of a2M variants on Ab1–42 fibril formation. (a) In vitro fibril formation of Ab1–42, incubated alone (black), with native a2M (red), with trypsin-a2M (blue), with
(i)trypsin-a2M (blue circles) or with NH4Cl-activated a2M (green), using a2M-to-Ab1–42 molar ratios of 1:10. (b) Percent of maximum ThT signal at the endpoint of
aggregation. Each bar represents the average of three individual experiments. (c) TEM analysis of the endpoint samples in the absence or presence of the different a2M
variants, with scale bars representing 100 nm and numbers corresponding to the lanes in gel analysis. (d) SDS–PAGE analysis of the endpoint supernatants shows no soluble
protein for Ab1–42 incubated alone (1), but soluble peptide present when incubated with native a2M (2). Incubation with trypsin-a2M (3) results in no full-length Ab1–42
peptide, whereas the incubation with (i)trypsin-a2M (4) and NH4Cl-activated a2M (5) have full-length peptide present. Lane M shows molecular mass markers. (d)
Fluorescence image of SDS–PAGE analysis of HiLyte-488 labelled Ab1–42, alone (lane 1) and after incubation with trypsin-a2M (lane 2) or (i)trypsin-a2M (lane 3). The presence
of trypsin-a2M results in an increase in Ab1–42 fragments (red arrow).
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containing Ab1–42 there is a small ThT fluorescence signal at the
start of the assay, likely to be due to some ThT positive aggregates
being present in the stock peptide solutions. This level remains
constant over the time course for the samples containing native
a2M, but decreases slightly in the presence of trypsin-a2M. We
suspect that this may be due to the ability of trypsin-a2M to de-
grade these ThT positive species.
TEM images of the ThT assay endpoint samples show that fibril-
lar aggregates are formed by Ab1–42 incubated alone; however, inthe presence of either native a2M or trypsin-a2M, the number of
well-defined fibrils is reduced and most aggregates appear to be
amorphous (Fig. 2c). Analysis of the endpoint supernatants by
SDS–PAGE reveals that incubation of Ab1–42 with trypsin-a2M re-
sults in proteolysis of the peptide (Fig. 2d, lane 3). This result is
consistent with previous work showing that a2M-trapped prote-
ases remain active against small substrates including Ab1–42 [22].
Therefore, it appears that trypsin-a2M prevents Ab1–42 fibril forma-
tion, under these conditions at least partly via degradation of the
Ab1–42 peptide to form smaller species that remain soluble.
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not be restricted to just Ab1–42. We have also observed that tryp-
sin-a2M can suppress the fibril formation of reduced and carbo-
xymethylated a-lactalbumin by a process which involves
proteolysis of the full-length protein (Supplementary Fig. 3).
Given that trypsin-a2M can degrade polypeptides which can
enter the activated a2M cage, it is necessary to inactivate the
bound trypsin to examine, in isolation, whether trypsin-a2M pos-
sesses chaperone activity similar to native a2M. Trypsin-a2M and
trypsin-a2M after treatment with a small molecule protease inhib-
itor ((i)trypsin-a2M) migrate similarly when analyzed by native
PAGE, suggesting that protease inactivation does not grossly affect
the structure of the covalent complex (Supplementary Fig. 1). Incu-
bation of fluorophore-labelled Ab1–42 with trypsin-a2M shows that
pre-treatment of the latter with protease inhibitors prevents
detectable proteolysis of Ab1–42 (Fig. 2e), however, the (i)trypsin-
a2M retains the ability to inhibit Ab1–42 aggregation (Fig. 2a, blue
circles). Significantly, analysis of the endpoint supernatants reveals
that soluble, full-length Ab1–42 is present in the (i)trypsin-a2M
sample and no degradation fragments are observed (Fig. 2d, lane
4). Analysis by TEM confirms that no fibrils are present in the
Ab1–42 sample containing (i)trypsin-a2M (Fig. 2c).
To confirm that chaperone activity of activateda2M is not reliant
on the presence of the bound protease, we tested the ability of NH4-
Cl activated-a2M to suppress fibril formation. Data from aggrega-
tion assays show that NH4Cl-activated a2M effectively suppresses
the ThT fluorescence associated with fibril formation by Ab1–42 pep-
tide or I59T lysozyme (Fig. 1a and Fig. 2a, green lines). TEM images
of the endpoint samples show that only traces of fibrillar species are
present in either the Ab1–42 or the I59T sample containing NH4Cl-
activated a2M. Furthermore, SDS–PAGE analysis of the endpoint
supernatants demonstrates that the presence of NH4Cl-activated
a2M increases the proportion of both client proteins remaining in
their soluble, full-length forms at the endpoint of the assays
(Fig. 1d, lane 4 and Fig. 2d lane 5). These results confirm that acti-
vated a2M can influence the solubility of polypeptides regardless
of whether or not it is complexed to a protease molecule.
4. Discussion
In the work presented here, we show that activated a2M, de-
spite a large conformational change upon activation, retains the
ability to suppress fibril formation. From earlier work, it is clear
that a2M has distinct binding sites for proteases and misfolded
proteins as the binding of a misfolded client protein does not pre-
vent protease trapping [6]. In the current study, we demonstrate
that the presence of a bound protease, regardless of whether or
not the protease is pharmacologically inhibited, does not signifi-
cantly reduce chaperone activity of a2M. Moreover, a2M remains
an active chaperone after direct activation using small molecules.
In vivo, activated a2M is rapidly cleared from circulation [2] and
typically represents only 0.17–0.7% of the total a2M in blood plas-
ma of adults [23]. The activated a2M plasma concentration is, how-
ever, increased in many disease states including pancreatitis,
multiple sclerosis and sepsis [23–25]. Moreover, the onset of some
diseases, such as periodontitis, diabetic retinopathy and inflamma-
tory joint disease results in increased activated a2M levels in other
extracellular fluids [26–28]. Although enhanced concentrations of
activated a2M have been largely attributed to increased protease
trapping, it has been reported that interaction with proteases only
partially accounts for the total activated a2M present in synovial
fluid [28]; higher levels of both protease-activated and amine-acti-
vated a2M may therefore be significant for facilitating clearance of
aberrant clients via LRP. Interestingly, aggregates of Ab1–40 and
amylin have been shown to activate the plasmin protease system[29]. Thus it is possible that concentrations of plasmin-activated
a2Mmay also be increased in response to the accumulation of mis-
folded proteins.
In conclusion, we provide evidence that protease-activated
a2M has two distinct mechanisms for inhibiting amyloid forma-
tion: (i) via protease–a2M-mediated degradation of amyloido-
genic substrates and (ii) by a chaperone action that prevents
misfolded clients from continuing along the amyloid forming
pathway. In the absence of proteases, activated a2M is able to in-
hibit fibril formation via the latter function only. It is tempting to
speculate that the chaperone activity of protease-activated a2M
may target misfolded proteins to the trapped protease, thereby
providing a specific mechanism for degradation of amyloidogenic
proteins in extracellular fluids. Clearly, further studies are re-
quired to substantiate this proposition; however, a greater under-
standing of the mechanisms by which a2M is able to prevent
protein aggregation and facilitate the disposal of misfolded pep-
tide and protein molecules could, in future, provide potential
therapeutic targets for amyloidosis.
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